X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA TTK HEALTHCARE NATCO PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 13.4 17.2 77.9% View Chart
P/BV x 3.8 5.6 68.5% View Chart
Dividend Yield % 1.2 0.5 223.7%  

Financials

 NATCO PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
TTK HEALTHCARE
Mar-14
NATCO PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,080663 162.8%   
Low Rs671399 168.2%   
Sales per share (Unadj.) Rs592.1535.6 110.5%  
Earnings per share (Unadj.) Rs188.415.9 1,181.5%  
Cash flow per share (Unadj.) Rs206.320.0 1,030.4%  
Dividends per share (Unadj.) Rs8.254.00 206.3%  
Dividend yield (eoy) %0.90.8 125.1%  
Book value per share (Unadj.) Rs833.6137.6 605.7%  
Shares outstanding (eoy) m36.907.77 474.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.51.0 149.1%   
Avg P/E ratio x4.633.3 14.0%  
P/CF ratio (eoy) x4.226.5 16.0%  
Price / Book Value ratio x1.13.9 27.2%  
Dividend payout %4.425.1 17.5%   
Avg Mkt Cap Rs m32,3114,127 782.8%   
No. of employees `0004.81.7 282.8%   
Total wages/salary Rs m3,256607 536.8%   
Avg. sales/employee Rs Th4,522.52,436.7 185.6%   
Avg. wages/employee Rs Th674.0355.2 189.8%   
Avg. net profit/employee Rs Th1,439.072.5 1,983.8%   
INCOME DATA
Net Sales Rs m21,8484,162 525.0%  
Other income Rs m40461 660.1%   
Total revenues Rs m22,2524,223 526.9%   
Gross profit Rs m9,284197 4,710.3%  
Depreciation Rs m66232 2,088.3%   
Interest Rs m15430 515.1%   
Profit before tax Rs m8,872197 4,510.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,92073 2,637.4%   
Profit after tax Rs m6,952124 5,611.0%  
Gross profit margin %42.54.7 897.3%  
Effective tax rate %21.637.0 58.5%   
Net profit margin %31.83.0 1,068.8%  
BALANCE SHEET DATA
Current assets Rs m21,3071,629 1,308.2%   
Current liabilities Rs m5,9201,058 559.7%   
Net working cap to sales %70.413.7 513.4%  
Current ratio x3.61.5 233.8%  
Inventory Days Days7330 246.0%  
Debtors Days Days10734 317.1%  
Net fixed assets Rs m14,986556 2,693.9%   
Share capital Rs m36978 474.9%   
"Free" reserves Rs m30,353878 3,455.9%   
Net worth Rs m30,7601,069 2,876.6%   
Long term debt Rs m0159 0.0%   
Total assets Rs m37,1512,399 1,548.3%  
Interest coverage x58.67.6 773.4%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.61.7 33.9%   
Return on assets %19.16.4 298.4%  
Return on equity %22.611.6 195.1%  
Return on capital %29.318.5 159.0%  
Exports to sales %00.8 0.0%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs mNA33 0.0%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m10,32233 31,373.1%   
Fx outflow Rs m2,97863 4,713.5%   
Net fx Rs m7,343-30 -24,243.3%   
CASH FLOW
From Operations Rs m4,636127 3,661.9%  
From Investments Rs m-11,155-146 7,640.4%  
From Financial Activity Rs m6,50922 29,721.5%  
Net Cashflow Rs m-183 -720.0%  

Share Holding

Indian Promoters % 52.0 65.4 79.6%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 5.2 319.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 25.8 100.8%  
Shareholders   25,395 12,723 199.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 15.3% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, TTK HEALTHCARE has posted a net profit of Rs 67 m (down 15.3% YoY). Sales on the other hand came in at Rs 2 bn (up 16.3% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 12, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS